10-K: Chain Bridge I Faces Delisting and Financial Headwinds After Business Combination Termination

Chain Bridge I, a blank check company, reported a net loss for 2024, a significant working capital deficit, and the termination of its proposed business combination with Phytanix Bio, leading to its delisting from Nasdaq and raising substantial doubt about its ability to continue as a going concern.

Summary

• Chain Bridge I, a Special Purpose Acquisition Company (SPAC), reported a net loss of approximately $1.4 million for the fiscal year ended December 31, 2024, a sharp decline from a net income of $7.6 million in 2023.
• As of December 31, 2024, the company had a working capital deficit of $884,195 and cash of $129,598.
• The proposed business combination with Phytanix Bio, announced on July 22, 2024, was mutually terminated on April 7, 2025.
• The company was delisted from Nasdaq on November 19, 2024, due to its failure to complete a business combination within 36 months of its IPO, and its securities now trade on the less liquid OTC Markets.
• The deadline to consummate an initial business combination has been extended to November 15, 2025, following shareholder approval on November 14, 2024.
• Significant Class A ordinary share redemptions occurred: approximately $197.85 million in May 2023, $34.5 million in February 2024, and $6.3 million in November 2024.
• As of June 16, 2025, the trust account held approximately $5,414,454, with an estimated pro rata redemption price of ~$11.88 per public share if the company liquidates.
• A material weakness in internal controls over financial reporting was identified, related to the understatement of the Bridge Financing Note liability by $200,000 in Q3 2024.
• Fulton AC I LLC (Fulton AC), a key related party, holds approximately 95.11% of the company's voting power and has agreed to reimburse the Trust Account up to $100,000 for dissolution expenses and contributes $4,557 monthly to the Trust Account.
• The company has outstanding balances of $296,942 under the Exchange Note (from Fulton AC) and $1,063,235 under the Bridge Financing Note (from Phytanix Bio) as of December 31, 2024.

Sentiment

Score: 3

Explanation: The overall sentiment is negative due to the net loss, significant working capital deficit, Nasdaq delisting, and the termination of the primary business combination target. While the deadline extension provides more time, the underlying financial and operational challenges are substantial, raising going concern doubts.

Positives

• The company successfully extended its business combination deadline to November 15, 2025, providing more time to identify a suitable target.
• Fulton AC has committed to reimburse the Trust Account up to $100,000 for dissolution expenses, potentially benefiting public shareholders upon liquidation.
• Fulton AC's ongoing monthly contributions to the Trust Account help maintain its value for public shareholders.
• The company regained compliance with Nasdaq's Public Shareholder Rule in September 2024, demonstrating some operational adherence, although it was subsequently delisted for other reasons.

Negatives

• The company reported a net loss of approximately $1.4 million for the year ended December 31, 2024, a significant reversal from a net income of $7.6 million in 2023.
• A substantial working capital deficit of $884,195 as of December 31, 2024, indicates liquidity challenges outside the trust account.
• The company was delisted from Nasdaq on November 19, 2024, and now trades on less liquid OTC Markets, which may adversely affect investors' ability to resell securities.
• The mutual termination of the Business Combination Agreement with Phytanix Bio signifies a major setback in achieving its primary objective.
• Significant shareholder redemptions have substantially reduced the funds available in the trust account for a business combination.
• Management identified a material weakness in internal controls over financial reporting related to the understatement of a liability, indicating control deficiencies.
• The company's ability to continue as a going concern is in substantial doubt due to its liquidity condition and the mandatory liquidation date if a business combination is not completed.
• Warrants will expire worthless if the company fails to consummate an initial business combination by November 15, 2025.
• Fulton AC holds a substantial 95.11% voting power, potentially limiting the influence of other shareholders on key decisions.

Risks

• The company has no operating history or revenues, providing no basis to evaluate its ability to achieve its business objective.
• Past performance of the management team or affiliates is not indicative of future performance.
• Shareholders may not be afforded an opportunity to vote on the proposed initial business combination.
• Fulton AC, CBG, CB Co-Investment, and current/former directors/officers have agreed to vote in favor of the initial business combination, regardless of public shareholder votes.
• The ability of public shareholders to redeem shares for cash may make the company's financial condition unattractive to potential business combination partners.
• A large number of redemptions could prevent the company from completing the most desirable business combination or optimizing its capital structure.
• The November 15, 2025, deadline for consummating a business combination may give potential partners leverage and limit due diligence time.
• The search for a business combination may be adversely affected by current or anticipated military conflicts (e.g., Russia-Ukraine, Israel-Hamas), terrorism, sanctions, changes to foreign trade policies, geopolitical events, pandemics (e.g., COVID-19 variants), and the status of debt and equity markets.
• Increased competition for business combination opportunities may make attractive targets scarcer and more expensive.
• If the company fails to consummate an initial business combination by November 15, 2025, it will cease operations, redeem public shares (estimated ~$11.88/share, or less), and warrants will expire worthless.
• Insufficient funds outside the trust account may limit the search for a partner business, requiring reliance on loans from Fulton AC or affiliates.
• Subsequent to a business combination, the company may be required to take write-downs, write-offs, restructuring, or impairment charges, negatively affecting financial condition and share price.
• Third-party claims against the company could reduce the proceeds held in the trust account, leading to a lower per-share redemption amount.
• Changes in the market for directors and officers liability insurance could make it more difficult and expensive to complete a business combination.
• Shareholders may fail to receive notice of redemption offers or comply with tendering procedures, losing their redemption rights.
• Public shareholders have no rights or interests in trust account funds except under specific limited circumstances.
• Instructing the trustee to hold trust account funds in cash (to mitigate investment company risk) would likely result in minimal interest, reducing redemption amounts.
• Cash balances in trust account bank accounts may exceed FDIC insurance limitations, posing a risk of loss.
• Delisting from Nasdaq to OTC Markets adversely affects liquidity and resale flexibility for investors.
• The company is exempt from certain SEC rules (e.g., Rule 419) normally protecting blank check company investors, meaning fewer protections.
• Shareholders holding over 15% of Class A ordinary shares may lose the ability to redeem excess shares without prior consent.
• The company may incur substantial debt to complete a business combination, adversely affecting leverage and financial condition.
• Lack of business diversification post-combination, as the company may only acquire a single business, increasing exposure to specific industry risks.
• Attempting simultaneous business combinations with multiple partners could hinder completion and increase costs/risks.
• Limited information available for private target companies may lead to less profitable business combinations.
• The management team may not be able to maintain control of a partner business after the initial business combination.
• Acquisition opportunities with high complexity requiring significant operational improvements could delay or prevent desired results.
• The absence of a specified maximum redemption threshold may allow completion of a business combination even if a substantial majority of shareholders disagree.
• The company's charter and other governing instruments, including warrant agreements, may be amended without shareholder approval.
• The lower amendment threshold (two-thirds vote) for pre-business combination activity provisions makes it easier to amend the charter.
• Shareholders may face difficulties protecting their interests or enforcing rights due to Cayman Islands incorporation and differences in corporate law.
• Cyber incidents or attacks could result in information theft, data corruption, operational disruption, and financial loss.
• Acquiring and operating a business in foreign countries introduces additional risks (e.g., currency fluctuations, political instability, regulatory changes).
• Post-combination management unfamiliar with United States securities laws could lead to regulatory issues.
• The company may be deemed a passive foreign investment company (PFIC), resulting in adverse U.S. federal income tax consequences for U.S. investors.
• After a business combination, if a majority of directors/officers live outside the U.S. and assets are abroad, enforcing U.S. federal securities laws or legal rights may be difficult.

Future Outlook

Chain Bridge I is actively seeking a new business combination partner, aiming to identify a growth-oriented, market-leading company. The company acknowledges the need for additional financing to complete a business combination if current funds are insufficient. The current economic environment and increased competition for SPAC targets are recognized challenges. The company intends to comply with SEC regulations and aims for a Nasdaq listing for the post-combination entity, despite its current delisted status.

Management Comments

• "Our business combination and value creation strategy is to identify and complete our initial business combination with a growth-oriented, market-leading company in an industry that complements the collective investment experience and expertise of our management team, and to build long-term shareholder value."
• "Our search will span across high growth areas such as technology, software, biotechnology and digital assets as well as traditional sectors such as industrials, business services and healthcare services."
• "We have not entered into any definitive agreements with respect to a potential business combination."
• "We do not expect the delisting to impact our ability to consummate the previously disclosed business combination with Phtytanix Bio (the Phytanix Business Combination)." (Note: This statement was made before the termination of the Phytanix Bio agreement.)
• "The Company is committed to ensuring compliance with the Investment Company Act and the updated SEC guidance. By adhering to the safe harbor provisions, the Company seeks to mitigate risks associated with the potential application of the Investment Company Act."

Industry Context

The document highlights a resurgence in the number of special purpose acquisition companies (SPACs) over the past year, leading to increased competition for attractive target businesses. This competitive landscape, coupled with global economic uncertainties such as military conflicts (Russia-Ukraine, Israel-Hamas), inflation, and rising interest rates, makes it more challenging for SPACs to find suitable acquisition targets and secure necessary financing. The company's delisting from Nasdaq to the OTC Markets is a significant negative development, placing it at a disadvantage compared to other SPACs that maintain major exchange listings, potentially hindering its ability to attract investors and complete a desirable business combination.

Comparison to Industry Standards

• The company's delisting from Nasdaq to the OTC Markets (OTCQB and Expert Market) is a significant underperformance compared to industry standards for SPACs, which typically aim for and maintain listings on major national exchanges like Nasdaq or NYSE.
• The termination of the business combination agreement with Phytanix Bio, following previous extensions and significant redemptions, indicates a struggle to execute its core SPAC strategy, contrasting with successful SPACs that complete their de-SPAC transactions.
• The reported net loss of $1.4 million in 2024, coupled with a working capital deficit, suggests financial underperformance compared to SPACs that manage to maintain a more stable financial position or generate investment income from their trust accounts.
• The high redemption rates experienced by Chain Bridge I (e.g., $197.85 million in May 2023, $34.5 million in Feb 2024, $6.3 million in Nov 2024) are indicative of a lack of shareholder confidence or attractiveness of proposed transactions, which is a common challenge for SPACs but can be more severe than industry averages.
• The identification of a material weakness in internal controls over financial reporting is a governance concern that could deter potential target companies and investors, contrasting with the robust internal controls expected of publicly traded entities and successful SPACs.

Management Changes

Corporate Governance

Related Party Transactions

• Fulton AC I LLC (Fulton AC) acquired 3,035,000 Class B ordinary shares and warrants to purchase 7,385,000 Class A ordinary shares from CBG and CB Co-Investment on December 29, 2023.
• CB Co-Investment irrevocably agreed to convert a $1.15 million loan into contingently issuable Private Placement Warrants upon consummation of a business combination.
• Fulton AC agreed to loan the Company up to $1.5 million via the Fulton AC Note (now Exchange Note), which is unsecured, non-interest bearing, and convertible into warrants.
• The Company pays Fulton AC up to $30,000 per month for office space, administrative, and support services under the Fulton Services Agreement.
• Fulton AC has agreed to reimburse the Trust Account up to $100,000 for dissolution expenses if the company is dissolved.
• Fulton AC contributes $4,557 per month to the Trust Account, commencing December 16, 2024, until the earliest of November 15, 2025, business combination, or winding up.
• RSUs were granted to directors (Mr. Silberman, Mr. Baron, Mr. Wiener) and former CFO (Mr. Lazarus) subject to business combination and equity incentive plan approval.
• Fulton AC, CBG, CB Co-Investment, and current/former directors/officers have agreed to vote their shares in favor of a business combination and waive redemption/liquidation rights for certain shares.
• Fulton AC, CBG, CB Co-Investment, and certain individuals entered into an amendment to the Letter Agreement, making Fulton AC liable for certain third-party claims against the trust account.

Stakeholder Impact

• Shareholders: Face significant risk of investment loss, particularly if a business combination is not completed by November 15, 2025, as warrants will expire worthless and redemptions may be less than anticipated due to creditor claims. The delisting to OTC Markets reduces liquidity and market transparency.
• Employees (Executive Officers/Directors): Compensation through RSU grants is contingent on a business combination. They may negotiate employment or consulting agreements with the post-combination company, potentially influencing their motivation in selecting a target.
• Creditors: The company's ability to pay creditors is uncertain, especially if it liquidates. Fulton AC has agreed to indemnify the trust account against certain claims, but its ability to satisfy these obligations is not independently verified.
• Potential Business Combination Partners: The company's financial condition (working capital deficit, reliance on loans) and high redemption rates may make it an unattractive partner. The delisting from Nasdaq could also deter potential targets seeking a major exchange listing.

Next Steps

• Identify and complete an initial business combination with one or more businesses by November 15, 2025.
• Potentially seek additional third-party financing to fund the business combination or post-combination operations.
• Continue to receive monthly contributions from Fulton AC into the Trust Account until the earlier of November 15, 2025, business combination, or winding up.
• Implement remediation steps to improve internal control over financial reporting, including enhancing review processes for complex securities and accounting standards, and considering additional qualified staff.

Key Dates

Recommendation

Keywords

SPAC, blank check company, SEC filing, 10-K, financial report, business combination, acquisition, delisting, OTC Markets, financial performance, liquidity, internal controls, shareholder redemptions, warrants, Cayman Islands, Phytanix Bio, Fulton AC, corporate governance, risk management